<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03459157</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12369 CohMSM-PrEP</org_study_id>
    <nct_id>NCT03459157</nct_id>
  </id_info>
  <brief_title>Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)</brief_title>
  <acronym>CohMSM-PrEP</acronym>
  <official_title>Access to Pre-exposure Prophylaxis for Men Who Have Sex With Men: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Expertise France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SESSTIM (IRD, Inserm, Université Aix-Marseille)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Coalition Internationale Sida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Médecine Tropicale, Anvers, Belgique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ARCAD-SIDA MALI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Association African Solidarité</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherche Internationale pour la Santé, Université de Ouagadougou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Espace Confiance, Côte d'Ivoire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Espoir Vie-Togo - ONG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratoire BIOLIM, Université de Lomé</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This demonstration project will assess the acceptability and feasibility of pre-exposure&#xD;
      prophylaxis (PrEP) for men who have sex with men (MSM) as part of a comprehensive HIV&#xD;
      prevention package in community-based clinics in West Africa.&#xD;
&#xD;
      An interventional, open label, multidisciplinary and multicentre cohort study will be&#xD;
      performed in Burkina Faso, Côte d'Ivoire, Mali, and Togo.&#xD;
&#xD;
      All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly&#xD;
      clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (daily or&#xD;
      on-demand, according the participant's choice), immunisation against hepatitis B,&#xD;
      individualised peer-led support (for adherence and prevention), group discussions, condoms,&#xD;
      and lubricants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This demonstration project will assess the acceptability and feasibility of pre-exposure&#xD;
      prophylaxis (PrEP) for men who have sex with men (MSM) as part of a comprehensive HIV&#xD;
      prevention package in community-based clinics in West Africa.&#xD;
&#xD;
      The specific objectives are to assess the acceptability of PrEP, the adherence to PrEP and to&#xD;
      quarterly HIV testing, the safety of daily and on-demand use of TDF/FTC, the impact of PrEP&#xD;
      on the other prevention strategies, the incidence of sexually transmitted infections (STIs)&#xD;
      on PrEP, the &quot;real life&quot; effectiveness of PrEP use and treatment-related resistance, and the&#xD;
      cost and cost-effectiveness of PrEP.&#xD;
&#xD;
      This interventional, open label, multidisciplinary and multicentre cohort study will be&#xD;
      performed in Burkina Faso, Côte d'Ivoire, Mali, and Togo.&#xD;
&#xD;
      All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly&#xD;
      clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (daily or&#xD;
      on-demand, according the participant's choice), immunisation against hepatitis B,&#xD;
      individualised peer-led support (for adherence and prevention), group discussions, condoms,&#xD;
      and lubricants.&#xD;
&#xD;
      These activities will be performed by community-based organisations which are pioneer in the&#xD;
      fight against HIV, especially in MSM. The study will have a total duration of 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">April 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of MSM under PrEP among eligible HIV-seronegative participants</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the acceptability of PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of MSM using daily and/ord on-demand PrEP</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the acceptability of PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of MSM followed after 3 years compared to the number of MSM included (retention in the program)</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the acceptability of PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of adherence reported by MSM</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the adherence to PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Counting of TDF/FTC tablets</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the adherence to PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of TDF and FTC</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the adherence to PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of HIV tests performed</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the adherence to quarterly HIV testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical and biological adverse events related to TDF and FTC</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the safety of daily and on-demand use of TDF/FTC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of condomless anal intercourse</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the evolution of the other prevention strategies on PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of sexual intercourse associated with alcohol and/or drug use</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the evolution of the other prevention strategies on PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of STIs</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the incidence of STIs on PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of HIV infection</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the &quot;real life&quot; effectiveness of PrEP use and the emergence of treatment-related resistance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of TDF/FTC resistance among MSM newly infected by HIV</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the &quot;real life&quot; effectiveness of PrEP use and the emergence of treatment-related resistance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total cost of the intervention over the study period and in the long term</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the cost and cost-effectiveness of PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incremental cost-effectiveness ratio of the intervention (versus no intervention) over the study period and in the long term</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the cost and cost-effectiveness of PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conditions of TDF/FTC price and of effectiveness for the intervention to be cost-effective in the study countries</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the cost and cost-effectiveness of PrEP</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">649</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>HIV prevention package including PrEP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIV prevention package including PrEP</intervention_name>
    <description>All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (TDF 300 mg + FTC 200 mg), daily or on-demand, according the participant's choice, immunisation against hepatitis B, individualised peer-led support (for adherence and prevention), group discussions, condoms, and lubricants.</description>
    <arm_group_label>HIV prevention package including PrEP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male (or transgender male person at birth)&#xD;
&#xD;
          -  At least 18 years old&#xD;
&#xD;
          -  HIV-seronegative&#xD;
&#xD;
          -  Having had at least one anal sex episode with another man within the previous 6 months&#xD;
&#xD;
          -  Having at least one of the following criteria:&#xD;
&#xD;
               -  Have a sexual partner (male or female) infected with HIV without evidence of&#xD;
                  virological suppression&#xD;
&#xD;
               -  Have had anal or vaginal sex episodes without condoms with more than one partner&#xD;
                  within the previous 6 months&#xD;
&#xD;
               -  Have had a sexually-transmitted infection (STI) within the previous 6 months&#xD;
                  (syndromic or biological approach, or mentioned by the participant)&#xD;
&#xD;
               -  Have received post-exposure prophylaxis for HIV within the previous 6 months&#xD;
&#xD;
               -  Wishing to reinforce its means of prevention through the use of PrEP&#xD;
&#xD;
          -  Accepting to participate in the study and signing the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical manifestations suggesting a primary HIV infection&#xD;
&#xD;
          -  Recent probable HIV exposure&#xD;
&#xD;
          -  Creatinine clearance &lt;60 mL/min calculated according to the Cockroft &amp; Gault formula&#xD;
&#xD;
          -  Positive or undetermined HBsAg&#xD;
&#xD;
          -  Allergy or contraindication to any of the components of PrEP&#xD;
&#xD;
          -  Participation in another biomedical and/or behavioral study on HIV or STIs (excluding&#xD;
             CohMSM)&#xD;
&#xD;
          -  Disability of the person making it difficult, if not impossible, to participate in the&#xD;
             study or understanding of the information given to him&#xD;
&#xD;
          -  Predictable non-compliance with the protocol (geographical distance, non-compliance&#xD;
             with monitoring or other reasons)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Oasis, Association African Solidarité</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de Confiance, Espace Confiance</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des Halles, ARCAD-SIDA</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Lucia, Espoir Vie Togo</name>
      <address>
        <city>Lomé</city>
        <country>Togo</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Côte D'Ivoire</country>
    <country>Mali</country>
    <country>Togo</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 2, 2018</study_first_submitted>
  <study_first_submitted_qc>March 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2018</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV infection</keyword>
  <keyword>Men who have sex with men</keyword>
  <keyword>Pre-exposure prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

